MOTS-c: a real discovery, but no human trial yet

MOTS-c is a genuine piece of biology: a 16-amino-acid peptide coded in our mitochondrial DNA, found in human blood, and raised by exercise [1,3]. Injected into mice, it prevented diet-induced obesity and insulin resistance and improved physical performance in old animals [1,3]. But when the FDA reviewed it in 2026, it found no published clinical study of MOTS-c given to humans by any route [10]. A first placebo-controlled trial started recruiting in February 2026 [14].

What it is

Almost all of your genes sit in the cell nucleus, but mitochondria, the cell's energy producers, carry a small genome of their own. In 2015 a team at the University of Southern California reported that a short stretch of mitochondrial DNA, inside the gene for a ribosomal RNA called 12S, encodes a 16-amino-acid peptide [1]. They named it MOTS-c: mitochondrial open reading frame of the 12S rRNA-c. Its sequence is MRWQEMGYIFYPRKLR.

In cells and mice, the team found that MOTS-c acts mainly on skeletal muscle. It slows the folate cycle and a linked pathway for building purines, which leads to activation of AMPK, a cellular energy sensor [1]. A 2018 follow-up found that under metabolic stress, such as glucose starvation, MOTS-c moves from the cytoplasm into the nucleus of cultured cells and switches on genes involved in antioxidant defence [2].

That is the mechanism story, and it comes from cells and mice. Nobody has shown it operating the same way in a person given the peptide.

The human evidence

The human data on MOTS-c are all observational: they measure the body's own MOTS-c, or look at people who carry a variant of it. None involves giving MOTS-c to people.

Exercise raises the body's own MOTS-c

In the 2021 study that also tested MOTS-c in mice, the researchers measured it in 10 sedentary young men before, during and after a bout of cycling, and found it rose in both muscle and blood [3]. A Swedish study of 30 adults found that endurance cycling produced a trend towards higher blood MOTS-c, which did not reach statistical significance, while resistance exercise had no clear effect [5]. In a 16-week exercise trial of 49 breast cancer survivors, MOTS-c rose in non-Hispanic white women but not Hispanic women [7]. These results point the same way but are small and not entirely consistent.

A genetic variant linked to diabetes

The most interesting human finding is genetic. Some people of Asian ancestry carry a mitochondrial DNA variant (m.1382A>C) that changes one amino acid in MOTS-c, swapping lysine for glutamine at position 14 [4]. In a combined analysis of three cohorts totalling 27,527 people, men with the variant had a higher prevalence of type 2 diabetes, especially if they were physically inactive; women did not [4]. In mice, the normal peptide lowered weight and improved glucose tolerance on a high-fat diet, but the variant form did not [4].

This is an association in one ethnic group, and it tells us the body's own MOTS-c may matter for metabolism in men. It says nothing about whether adding extra MOTS-c by injection does anything.

MOTS-c levels in people with more fat

One awkward finding: in 125 Chinese adults without diabetes, blood MOTS-c was higher, not lower, in people with metabolic syndrome, and tracked with waist size and liver fat [6]. The authors suggested the body may release it as a stress response. It also shows that "low MOTS-c causes obesity" is too simple.

Measuring it is hard

A doping-control lab trying to build a reliable test found that a commercial antibody kit reported MOTS-c levels in healthy people of 45.9–218.5 ng/mL, which its more specific mass-spectrometry method could not confirm [8]. Many human MOTS-c studies rely on such kits, so the absolute numbers should be read cautiously. The same lab also found MOTS-c breaks down quickly in human blood in the test tube [8], a point the FDA later raised when asking whether injected MOTS-c could reach useful levels [10].

Trials of MOTS-c itself

Two are registered. A company called CohBar ran a phase 1a/1b trial of CB4211, a compound it developed from MOTS-c rather than MOTS-c itself, in 88 healthy adults and people with fatty liver; it completed in April 2021 [13], and we could not find its results in any peer-reviewed journal. A phase 2a trial testing 12 weeks of daily MOTS-c injections against placebo in 120 adults with prediabetes and overweight started in February 2026 and is due to finish in 2028 [14].

What the human data add up to

Put together, the human studies support two modest claims. The body makes MOTS-c and releases more of it with some kinds of exercise [3,5,7]. And a naturally weaker version of the peptide is linked to diabetes in inactive men of Asian ancestry [4]. Neither claim tells you what happens when someone injects synthetic MOTS-c on top of what their mitochondria already make, at doses worked out from mice. That question has simply not been tested in a published study.

It's also worth being clear about what exercise itself does. Much of what MOTS-c is said to offer, including better insulin sensitivity, more muscle endurance and activation of AMPK, overlaps with what regular exercise does. The mouse research is interesting partly because it suggests MOTS-c may be one of the signals through which exercise works [3].

What the animal and lab work suggests

The mouse data are the reason for the interest. All of the following were in mice or cultured cells:

• MOTS-c injections prevented both age-related and high-fat-diet insulin resistance and diet-induced obesity [1].
• In young, middle-aged and old mice, MOTS-c improved running performance; treatment started very late in life (23.5 months, three times a week) improved physical capacity [3]. The late-life doses were 15 mg per kg of body weight, given by injection [3]; no dose of MOTS-c has been tested in people in a published study [10].
• Under glucose restriction in cells, MOTS-c entered the nucleus and regulated stress-response genes [2].

A 2023 review of the field summarised the animal promise but concluded that no effective way of using MOTS-c in the clinic had yet been developed [9]. Three years later, that still holds.

Safety and side effects

There are no human safety data. The FDA's 2026 review found no clinical studies or human exposure data for MOTS-c by any route, no pharmacokinetic studies in people, and no toxicity studies in animals to guide safe use [10]. Its search of the FDA adverse event database found no reports, which likely reflects how little formal reporting there is rather than proof of safety [10].

The agency also raised general concerns for injected peptides made outside drug manufacturing controls: immune reactions, aggregation and impurities [10]. The molecular targets of MOTS-c are not fully known, the FDA noted, which makes it hard to predict which organs might be affected [10].

Legal and regulatory status

The uses the FDA reviewed for MOTS-c were obesity and osteoporosis [11]. A favourable committee vote is not evidence that it works for either.

What we still don’t know

• Whether MOTS-c given to people does anything at all; the first placebo-controlled trial is not due to finish until 2028 [14].
• What happened in the CB4211 analogue trial, which completed in 2021 without published results [13].
• Whether injected MOTS-c survives long enough in human blood to act [8,10].
• Why blood levels are higher in people with more liver fat, if the peptide is protective [6].
• Whether the mouse effects on running capacity in old age have any human equivalent [3].

What readers report

First-hand accounts, shared with permission. They are self-reported, not evidence, and sit alongside the research above rather than in place of it.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR × Proper Protocols · Free · live online · with Q&A